Residency · Residency · Pediatrics
Sickle Cell Disease
Introduction
Sickle cell disease (SCD) encompasses a group of inherited hemoglobin disorders caused by a point mutation in the beta-globin gene (Glu6Val), producing hemoglobin S (HbS). Under deoxygenated conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. This leads to chronic hemolytic anemia, vaso-occlusion, and progressive organ damage. SCD affects approximately 100,000 individuals in the United States and millions worldwide, predominantly those of African, Mediterranean, Middle Eastern, and South Asian descent.
Genetics and Pathophysiology
Sickle cell disease follows autosomal recessive inheritance. Carriers with sickle cell trait (HbAS) are generally asymptomatic but can experience complications at extremes of exertion or altitude. The most common genotypes include HbSS (sickle cell anemia), the most severe form resulting from homozygosity for HbS; HbSC, a compound heterozygous state that is generally milder but carries higher risk for retinopathy and avascular necrosis; and HbS-beta-thalassemia, where HbS-beta0 is severe and similar to HbSS while HbS-beta+ is milder.
The core pathophysiology begins with HbS polymerization, which causes RBC rigidity and sickling. This drives vaso-occlusion through adhesion of sickled cells to the vascular endothelium, formation of microthrombi, and tissue ischemia. Chronic hemolysis shortens the RBC lifespan dramatically from the normal 120 days to just 10-20 days, resulting in elevated LDH, indirect bilirubin, and reticulocyte count. Free hemoglobin released during hemolysis scavenges nitric oxide, contributing to endothelial dysfunction, vasculopathy, pulmonary hypertension, and stroke risk. Fetal hemoglobin (HbF) inhibits HbS polymerization, so higher HbF levels are associated with milder disease.
Newborn Screening and Diagnosis
Universal newborn screening detects SCD via hemoglobin electrophoresis or HPLC. The HbSS pattern shows FS (HbF plus HbS with no HbA), HbSC shows FSC, and sickle trait shows FAS (HbF plus HbA plus HbS, with HbA predominant). Confirmatory testing is performed at 6-12 months when HbF levels decline.
Major Complications and Management
Vaso-Occlusive Pain Crisis (VOC)
Vaso-occlusive pain crises are the most common reason for ED visits and hospitalization in SCD. They are triggered by cold exposure, dehydration, infection, hypoxia, and stress. Management centers on aggressive hydration at 1-1.5 times maintenance IV fluids, multimodal analgesia with IV opioids (morphine or hydromorphone) plus NSAIDs and acetaminophen, warming, and incentive spirometry to prevent acute chest syndrome. Clinicians should avoid fluid overload, excessive opioids causing respiratory depression, and undertreatment of pain.
Acute Chest Syndrome (ACS)
Acute chest syndrome is the leading cause of death in SCD. It is defined by a new pulmonary infiltrate plus at least one of the following: chest pain, fever, tachypnea, cough, or hypoxia. Causes include infection (Chlamydia pneumoniae, Mycoplasma, viral pathogens), fat embolism from bone marrow infarction, and in situ pulmonary thrombosis. Treatment involves supplemental oxygen, IV antibiotics (a cephalosporin plus a macrolide), simple or exchange transfusion if severe (with a goal HbS less than 30%), incentive spirometry, and bronchodilators.
Stroke
Eleven percent of children with HbSS will have a clinical stroke by age 20 without intervention. Transcranial Doppler (TCD) ultrasonography is used for annual screening starting at age 2 through at least age 16. A time-averaged mean velocity (TAMV) of 200 cm/sec or greater indicates high risk and warrants initiation of chronic transfusion therapy to reduce HbS to less than 30%. In the setting of acute stroke, immediate exchange transfusion is required, targeting HbS less than 30% with a total Hb of 10 g/dL. Simple transfusion to Hb greater than 10 should be avoided because of the risk of hyperviscosity.
<image>Diagram illustrating the pathophysiology of sickle cell disease showing HbS polymerization under deoxygenation, RBC sickling, vaso-occlusion in small vessels, and downstream complications including pain crisis, acute chest syndrome, stroke, and organ damage</image>
Splenic Sequestration
Splenic sequestration involves acute trapping of blood in the spleen, causing rapid splenic enlargement, a falling hemoglobin (a drop of 2 g/dL or more from baseline), and hypovolemic shock. It is most common in children ages 6 months to 5 years, before autosplenectomy occurs in HbSS. Treatment consists of immediate volume resuscitation and simple transfusion, with splenectomy recommended after two or more episodes. Parent education on palpating the spleen is critical for early detection.
Aplastic Crisis
Aplastic crisis results from transient red cell aplasia caused by parvovirus B19 infection. There is an abrupt drop in hemoglobin with absent reticulocytes. The condition is usually self-limited over 7-10 days, with transfusion provided if symptomatic anemia develops.
Infections
Functional asplenia develops by age 5 in HbSS due to repeated infarction, increasing susceptibility to encapsulated organisms including Streptococcus pneumoniae, Haemophilus influenzae, and Salmonella (a common cause of osteomyelitis in SCD). Penicillin prophylaxis should begin by age 2 months and continue until at least age 5. Complete pneumococcal vaccination with the PCV15/20 series plus PPSV23 at ages 2 and 5 is essential. Fever in a child with SCD is a medical emergency: any temperature of 38.5C or higher requires urgent evaluation with blood culture and empiric parenteral antibiotics (ceftriaxone), without waiting for results.
<image>Management timeline for sickle cell disease in childhood showing age-based milestones: newborn screening confirmation, penicillin prophylaxis initiation at 2 months, transcranial Doppler screening starting at age 2, immunization schedule, hydroxyurea consideration at 9 months, and transition planning in adolescence</image>
Disease-Modifying Therapies
Hydroxyurea
Hydroxyurea is the first-line disease-modifying therapy for all children with HbSS or HbS-beta0 thalassemia, starting at 9 months of age per NHLBI guidelines. It works by increasing HbF production, reducing WBC and platelet counts, and improving RBC hydration and nitric oxide metabolism. Its benefits include reductions in VOC frequency, ACS episodes, transfusion needs, hospitalizations, and mortality. Dosing begins at 20 mg/kg/day and is escalated to the maximum tolerated dose, typically 25-35 mg/kg/day. Monitoring requires a CBC every 4-8 weeks during titration, with the medication held if ANC falls below 1,250, platelets below 80,000, or reticulocytes below 80,000.
Chronic Transfusion Therapy
Chronic transfusion therapy is indicated for primary or secondary stroke prevention, recurrent ACS, and severe symptomatic anemia. The goal is to maintain HbS less than 30% for stroke prevention or less than 50% for other indications. Complications include iron overload, which requires chelation with deferasirox or deferoxamine, and alloimmunization, which necessitates the use of extended antigen-matched RBCs with at minimum C, E, and K matching.
Newer Therapies
| Therapy | Mechanism | Key Benefit | Status |
|---|---|---|---|
| Hydroxyurea | Increases HbF, reduces WBC/platelets | Reduces VOC, ACS, mortality | First-line for all HbSS/HbS-beta0 from 9 months |
| Voxelotor | HbS polymerization inhibitor | Increases hemoglobin | FDA-approved age ≥4 |
| Crizanlizumab | Anti-P-selectin antibody | Reduces VOC frequency | FDA-approved age ≥16 |
| L-glutamine | Reduces oxidative stress | Reduces VOC | FDA-approved age ≥5 |
| Gene therapy (lovotibeglogene) | Gene addition | Potentially curative | FDA-approved 2023 |
| Gene editing (exagamglogene) | CRISPR-Cas9 | Potentially curative | FDA-approved 2023 |
| HSCT (matched sibling) | Allogeneic transplant | Curative (90-95%) | Established curative therapy |
Several newer therapies have expanded the treatment landscape. Voxelotor is an HbS polymerization inhibitor that increases hemoglobin by reducing sickling. Crizanlizumab is an anti-P-selectin monoclonal antibody that reduces VOC frequency. L-glutamine reduces oxidative stress in sickled RBCs. Gene therapy approaches, including autologous stem cell transplant with gene addition (lovotibeglogene) and gene editing using CRISPR-Cas9 (exagamglogene autotemcel), are potentially curative.
Hematopoietic Stem Cell Transplant (HSCT)
HSCT is the only established curative therapy, with the best outcomes achieved using an HLA-matched sibling donor. The cure rate is approximately 90-95% with a matched sibling, and experience with haploidentical donors is increasing. Indications include stroke, recurrent ACS, and severe VOC despite hydroxyurea.
<image>Comparison chart of disease-modifying therapies for sickle cell disease showing mechanisms of action, indications, key monitoring parameters, and relative efficacy for hydroxyurea, chronic transfusion, voxelotor, crizanlizumab, and gene therapy approaches</image>
Clinical Pearls
Fever in a child with SCD is a medical emergency because encapsulated organism sepsis can progress to death within hours. Hydroxyurea should be offered to all children with HbSS or HbS-beta0 thalassemia starting at 9 months, yet it remains underutilized. Clinicians should not transfuse above Hb 10 g/dL in SCD because hyperviscosity can worsen sickling and precipitate stroke. Transcranial Doppler screening prevents stroke and must be performed annually from age 2 to 16. Pain management must be individualized, as undertreated pain is a major source of patient distrust and healthcare disparities.
References
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA. 2014;312(10):1033-1048.
- Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle Cell Disease. Lancet. 2017;390(10091):311-323.
- DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Prevention, Diagnosis, and Treatment of Cerebrovascular Disease in Children and Adults. Blood Adv. 2020;4(8):1554-1588.
- Kato GJ, Piel FB, Reid CD, et al. Sickle Cell Disease. Nat Rev Dis Primers. 2018;4:18010.
